Can a bone marrow test predict who responds to a new AML combo?
NCT ID NCT02583893
First seen May 29, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This study tested whether adding sirolimus (a drug that blocks cancer cell growth) to standard MEC chemotherapy improves outcomes in 39 patients with high-risk acute myeloid leukemia (AML). Researchers also checked if biomarkers in bone marrow samples could predict who would respond. The goal was to see if this combination could lead to more remissions in a tough-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ADULT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sirolimus (Rapamycin) combined with chemotherapy (Mitoxantrone, Etoposide, Cytarabine)
What this could lead to
If successful, this approach could improve response rates in high-risk AML by using sirolimus to block cancer growth pathways, potentially leading to better outcomes for patients with limited options.
What could go wrong
This is a small Phase 2 trial (39 participants) focused on biomarkers, not a definitive test of effectiveness. The combination may not work for all patients, and chemotherapy carries significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.